Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Br J Haematol
; 199(3): 366-370, 2022 11.
Article
in En
| MEDLINE
| ID: mdl-35892294
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Follicular
/
Lymphoma, Large B-Cell, Diffuse
/
Antibodies, Bispecific
/
Receptors, Chimeric Antigen
/
Antineoplastic Agents
Type of study:
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Br J Haematol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: